This report describes two patients with germ cell tumors who underwent tandem autologous peripheral stem cell transplants. The chemotherapy consisted of high-dose carboplatin and etoposide. Both patients developed chemotherapy-related toxicities, which included nephrotoxicity in one case and febrile neutropenia, thrombocytopenia, ototoxicity and mucositis in both. During the second transplant, both patients received amifostine 15 min before and 2 h after each dose of carboplatin. The patients had less mucositis and nephrotoxicity. The duration of neutropenia and thrombocytopenia was less in both cases resulting in a decreased use of antibiotics and platelet transfusions. These cases suggest that the use of amifostine may be of benefit in minimizing toxicities associated with highdose chemotherapy. Bone Marrow Transplantation (2000) 26, 1247-1249.
num-induced nephrotoxicity. Chemically it is ethanethiol,2-[(3-aminopropyl)amino]dihydrogen phosphate ester or WR2721. Developed at the Walter Reed Army Institute of Research, amifostine was selected as the best candidate to protect troops from the myelosuppressive effects of radiation. 3 Amifostine is rapidly dephosphorylated by alkaline phosphatase present on the plasma membrane of the arteriolar endothelium of normal tissues and on the plasma membrane of renal proximal tubular epithelium, to form the active metabolite 'WR-1065' (containing free thiol). 4 Once inside the cell, the free thiol moiety can bind and neutralize reactive species of cisplatin.
In this report, we studied the efficacy of amifostine given as a chemoprotectant during conditioning for a second stem cell graft. Both patients experienced substantial toxicity due to high-dose carboplatin during the first of two planned consecutive transplants. Sensorineural hearing loss and severe mucositis were seen in both patients and nephrotoxicity was seen in one. The preparative regimen for both transplants in each patient was identical and consisted of etoposide 750 mg/m 2 and carboplatin 700 mg/m 2 administered intravenously daily over 15 min for 3 consecutive days (day −6 to day −4). Patients received G-CSF-mobilized autologous peripheral blood stem cell transplantation on day 0. G-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) 5 g/kg was given by subcutaneous injection daily starting day 6 post transplant until ANC Ͼ1 × 10 9 cells/l. We attempted to minimize the toxicity of the second transplant by pre-treating with amifostine, an agent known to reduce cisplatin-associated nephrotoxicity. 5 It was reasoned that amifostine may have similar protective effects on carboplatin-associated neurotoxicity. 
Case 1
A 25-year-old male with NSGCT received four cycles of cisplatin, etoposide and bleomycin. The patient underwent surgical resection for residual tumor and was given two additional cycles of cisplatin and etoposide. Four months later, a CT scan showed new retroperitoneal disease causing bilateral ureteral obstruction and renal failure (serum creatinine of 5.0 mg/dl). Bilateral ureteral stents were placed and the serum creatinine slowly normalized. The patient received the first preparative regimen with stem cell sup-port. The clinical course was complicated by febrile neutropenia, grade IV mucositis, renal failure, and hearing loss. Tumor response was documented by CT scan and normalization of tumor markers. Audiometry showed a 20% reduction in the right ear and 16% in the left ear from the baseline. For the second transplant, amifostine was administered (500 mg in 50 ml of normal saline over 15 min) 15 min before each dose of carboplatin and 2 h after completion of each daily infusion of carboplatin. This transplant was associated with febrile neutropenia and grade III mucositis but no significant nephrotoxicity. The severity of mucositis was significantly reduced in the second transplant and required 5 days of a morphine drip (at a dose of 0.75 mg/h) compared with 11 days in the first transplant at a higher dose (4 mg/h). There was no further impairment of hearing after the second transplant. There was no hypotension, nausea or emesis associated with the administration of the amifostine.
Case 2
A 33-year-old male with NSGCT tumor originally presented with an enlarged testicle, an ␣-fetoprotein of 19 409 ng/ml (normal, Ͻ10 ng/ml) and a ␤-HCG of 677 mIU/ml (normal, 0-5 mIU/ml). CT scan revealed pulmonary, hepatic and retroperitoneal metastases. The patient was initially treated with cisplatin, etoposide and bleomycin for four cycles with a partial response. A left orchiectomy was performed followed by one course of vinblastine, ifosfamide and cisplatin. His disease progressed despite salvage therapy. The patient then underwent tandem transplants. The first transplant was complicated by fever with neutropenia, grade IV mucositis, peripheral neuropathy, tinnitus, and hearing loss. The second transplant which included pretreatment with amifostine was complicated by a spontaneous pneumothorax, presumably from tumor necrosis. Despite the pain associated with the thoracostomy tube, the patient required 1 day less of parenteral analgesia than for the first transplant. Both the severity and duration of mucositis was reduced with the use of amifostine. Sensorineural hearing decreased 33% in the right ear and 50% in the left after the first transplant but remained unchanged after the second transplant. There were no side-effects associated with the administration of the amifostine. 
Discussion
Persons with testicular germ cell tumor, either refractory or in relapse after primary chemotherapy, have a 5-year progression-free survival of less than 25% after salvage therapy. 7, 8 To improve prognosis, patients often receive high-dose platinum-based chemotherapy with autologous stem cell support. Investigators at Indiana University have pioneered the use of tandem high-dose chemotherapy cycles with etoposide and carboplatin, followed by autologous stem cell support after each cycle.
1 While many patients have been cured with this approach, substantial morbidities including peripheral neuropathy, sensorineural hearing loss, mucositis, sepsis, renal and hepatic insufficiency have been observed.
For these two patients treated with high-dose carboplatin and tandem transplants, amifostine appeared to attenuate toxicities seen during the first transplant. There was lessened nephrotoxicity when amifostine was used as a chemoprotectant in one patient. In both cases, there was a decrease in the severity and duration of mucositis, a shorter duration of platelet transfusion dependency, and a decrease in the number of days on antibiotics (Table 1) . It is less clear whether amifostine protected against neurotoxicity, although the lack of progressive hearing loss may be indicative of its protective effect.
Several investigators suggest that amifostine has a broad spectrum of chemoprotective activity with amelioration of myelotoxicity, nephrotoxicity, esophagitis, xerostomia, and oral mucositis. 6 The largest published study involved 242 women with advanced ovarian cancer, randomized to receive six cycles of cyclophosphamide 1000 mg/m 2 and cisplatin 100 mg/m 2 with or without amifostine dose of 910 mg/m 2 . 9 The authors concluded that pretreatment with amifostine reduces the cumulative hematological, renal, and neurological toxicities without reduction in antitumor efficacy.
We elected to treat each patient with a fixed dose of 1000 mg of amifostine for each of the 3 days of chemotherapy treatment. Amifostine was administered in two divided doses of 500 mg each given 15 min before and 2 h after carboplatin infusion. We reasoned that amifostine blood levels might not be maintained long enough on a once daily schedule to cover the long half-life of high-dose carboplatin, which might be further prolonged with concomitant administration of amifostine. 10 The dose schedule of amifostine described in our patients appeared to be efficacious in attenuating the toxicities of carboplatin. Furthermore, there were no toxicities attributed to amifostine.
A theoretical concern about the use of amifostine is the possibility of tumor protection. In the previously mentioned study in advanced ovarian cancer, there was no difference in survival in the patients treated with amifostine.
